Heart failure & cardiomyopathiesCohort study
Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction
- Retrospective cohort study
- single-centre
- time-varying multivariate Cox regression
Authors' conclusion
Maintaining RAS inhibitors and beta-blockers was associated with a significantly lower incidence of relapse in the setting of AiCM with improved LVEF.
Study context
- Population
- Patients admitted for heart failure (HF) with left ventricular ejection fraction (LVEF) <50% and arrhythmia considered the precipitating cause (suspected arrhythmia-induced cardiomyopathy), with LVEF improvement188 with confirmed arrhythmia-induced cardiomyopathy (AiCM)
- Participants
- 200 patients
- Exposure
- GDMT classes vs not, after LVEF improvement
- Outcome
- Time to HF relapse (readmission for HF, ED visit for HF, or significant decline in LVEF)
- Follow-up
- Median 6.14 years
Main finding
As reported in the abstract
HF relapse
Adjusted hazard ratio (CI)P value
RAS inhibitors
0.50(0.31–0.81)
P = 0.005Beta-blockers
0.48(0.28–0.81)
P = 0.006- Patients meeting the primary endpoint
- 89 (47.3%)
Observational data: associations, not effects.
Further findings
Emergency Department (ED) visits for HF
| Comparison | adjusted HR (CI) | P value | |
|---|---|---|---|
| MRA | 0.38 (0.15–0.95) | P = 0.038 | |
| 0.10.31310Adjusted hazard ratio (log scale) |
Original publication
Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction. Eur J Heart Fail. Published 18 December 2024. doi:10.1002/ejhf.3556
Summarised from the published abstract; every number is checked against it